PSMA-guided radiation boost for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have prostate cancer that is intermediate-risk or high-risk (as determined by your doctor).
- You had an MRI in the last 6 months that found at least one suspicious area (PI-RADS 4 or 5).
- You had a PSMA PET scan in the last 6 months that shows a bright spot in your prostate matching the MRI finding.
- Your cancer has not spread to lymph nodes or other organs.
- You have not had prior hormone therapy, radiation to the pelvis, or prostate surgery (including TURP).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET/MR scan to help doctors aim stereotactic radiation more precisely for certain higher-risk or unfavorable intermediate prostate cancers. It studies whether this targeted approach can safely treat the prostate (and specific areas needing extra treatment) without spreading to the body.
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This study tests a new radiation treatment approach that uses MRI imaging to target specific tumor areas within the prostate while reducing radiation to healthy tissue. It may help patients with early-stage prostate cancer get effective treatment with fewer side effects.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This study tests whether adding a stronger, focused radiation “boost” to a visible prostate spot—using real-time MRI guidance—can improve treatment for locally advanced prostate cancer. It may help better control the tumor while still delivering standard radiation to the rest of the prostate area.
Hear when a new High Risk Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.